Competing interestsThe authors declare that they have no competing interests.Authors’ contributionsDAO, FB, FG, ROL and JFBM assisted in the design of the study, coordinated patient recruitment, analysed and interpreted the data and assisted in writing the paper. SR, ET, JME, RA and MN assisted in the analysis and interpretation of data and in writing the selleck report. VI, LR, AML, CN, RD and ER performed the laboratory work. All authors read and approved the final manuscript for publication.Supplementary MaterialAdditional file 1:Comparison of immunological parameters based upon ICU mortality in patients with septic shock. Data are medians [IQR]. n.s = not significant.
Normal values in healthy adults are as follows: immunoglobulin G (IgG) = 870 to 2,180 mg/dl; IgA = 117 to 420 mg/dl; IgM = 60 to 220 mg/dl; CD3+ T cells = 690 to 2,540 cells/mm3; CD4+ T cells = 410 to 1,590 cells/mm3; CD8+ T cells = 190 to 1,140 cells/mm3; CD4+CD8+ T cells = not available; B lymphocytes (LB) = 90 to 660 cells/mm3; natural killer (NK) cells = 90 to 590 cells/mm3; complement factor 3 (C3) = 50 to 120 mg/dl; complement factor 4 (C4) = 14 to 70 mg/dl.Click here for file(71K, DOC)Additional file 2:Comparison of immunological parameter levels over time. Changes in the levels of immune parameters over time in survivors and nonsurvivors were assessed using the Wilcoxon signed-rank test. The results are expressed as medians (IQR) of the increments (day 3 – day 1) and (day 10 – day 1). IgG = immunoglobulin G; IgM = immunoglobulin M; IgA = immunoglobulin A; C3: complement factor 3; C4: complement factor 4; NK cells: natural killer cells; LB = B lymphocytes.
Click here for file(74K, DOC)NotesSee related letter by Pablo et al., http://ccforum.com/content/16/2/413AcknowledgementsThe authors thank the ICU nursery team, which kindly collected the samples for the study, and Dr Antonio Ordu?a for providing logistical support for this work. This study was made possible by a grant from the Spanish Ministry of Science and Innovation and the ‘Consejer��a de Sanidad Junta de Castilla y Le��n’ (‘Programa para favorecer la incorporaci��n de grupos de investigaci��n en las Instituciones del Sistema Nacional de Salud’, EMER07/050, y ‘Proyectos de Investigaci��n Sanitaria’, PI 10/01362).
Approximately 1 million sudden cardiac arrests occur each year in the United States and Europe [1]. Although the initial return of spontaneous circulation (ROSC) after cardiac arrest (CA) is achieved in about 30% to 40% of cases, only 10% to 30% of these patients admitted Dacomitinib to the hospital are discharged with good neurological outcomes.